Perdiguero, Beatriz and Elena Gomez, Carmen and Garcia-Arriaza, Juan and Sanchez-Corzo, Cristina and Sorzano, Carlos Oscar S. and Wilmschen, Sarah and von Laer, Dorothee and Asbach, Benedikt and Schmalzl, Christina and Peterhoff, David and Ding, Song and Wagner, Ralf and Kimpel, Janine and Levy, Yves and Pantaleo, Giuseppe and Esteban, Mariano (2019) Heterologous Combination of VSV-GP and NYVAC Vectors Expressing HIV-1 Trimeric gp145 Env as Vaccination Strategy to Induce Balanced B and T Cell Immune Responses. FRONTIERS IN IMMUNOLOGY, 10: 2941. ISSN 1664-3224,
Full text not available from this repository. (Request a copy)Abstract
The generation of a vaccine against HIV-1 able to induce durable protective immunity continues a major challenge. The modest efficacy (31.2%) of the phase III RV144 clinical trial provided the first demonstration that a prophylactic HIV/AIDS vaccine is achievable but emphasized the need for further refinements of vaccine candidates, formulations, and immunization regimens. Here, we analyzed in mice the immunogenicity profile elicited by different homologous and heterologous prime/boost combinations using the modified rhabdovirus VSV-GP combined with DNA or poxviral NYVAC vectors, all expressing trimeric membrane-bound Env (gp145) of HIV-1 96ZM651 clade C, with or without purified gp140 protein component. In cultured cells infected with recombinant VSV-GP or NYVAC viruses, gp145 epitopes at the plasma membrane were recognized by human HIV-1 broadly neutralizing antibodies (bNAbs). In immunized mice, the heterologous combination of VSV-GP and NYVAC recombinant vectors improved the induction of HIV-1 Env-specific humoral and cellular immune responses compared to homologous prime/boost protocols. Specifically, the combination of VSV-GP in the prime and NYVAC in the boost induced higher HIV-1 Env-specific T cell (CD4/CD8 T cells and T follicular helper -Tfh- cells) immune responses compared to the use of DNA or NYVAC vectors in the prime and VSV-GP in the boost. Such enhanced T cell responses correlated with an enhancement of the Env-specific germinal center (GC) B cell population and with a heavily biased Env-specific response toward the Th1-associated IgG2a and IgG3 subclasses, while the other groups showed a Th2-associated IgG1 bias. In summary, our T and B cell population data demonstrated that VSV-GP-based vectors could be taken into consideration as an optimized immunogenic HIV-1 vaccine candidate component against HIV-1 when used for priming in heterologous combinations with the poxvirus vector NYVAC as a boost.
| Item Type: | Article |
|---|---|
| Uncontrolled Keywords: | BROADLY NEUTRALIZING ANTIBODIES; VESICULAR STOMATITIS-VIRUS; IMMUNODEFICIENCY-VIRUS; RHESUS MACAQUES; TFH CELLS; DNA PRIME; IN-VIVO; STRAIN; IMMUNOGENICITY; ACTIVATION; HIV-1 Env; vaccine; VSV-GP; NYVAC; mice immunization; T and B cells; antibodies; immune correlates |
| Subjects: | 600 Technology > 610 Medical sciences Medicine |
| Divisions: | Medicine > Lehrstuhl für Medizinische Mikrobiologie und Hygiene |
| Depositing User: | Dr. Gernot Deinzer |
| Date Deposited: | 20 Mar 2020 07:11 |
| Last Modified: | 20 Mar 2020 07:11 |
| URI: | https://pred.uni-regensburg.de/id/eprint/25668 |
Actions (login required)
 |
View Item |
